Wire · opportunities
FDA Approves Durvalumab Plus Enfortumab Vedotin for Cisplatin-Ineligible MIBC
◆ Sectors
Biotech
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 13 November 2026 · Fusion42 review
The FDA has approved the combination of durvalumab and enfortumab vedotin for treating patients with muscle-invasive bladder cancer who are ineligible for cisplatin chemotherapy.
This Wire brief sits within Fusion42's coverage of Biotech, and 6 sources have reported it.
◆ ◆ The Wire takeaway
FDA’s approval opens a clear path for new bladder cancer therapies catering to cisplatin-ineligible patients, marking a fresh opportunity to target an underserved group in oncology drug development.
◆ Coverage
6 sources · 13 Nov 2026
◆ Related on Wire
◆ Topics
Biotechfda-approvalbladder-cancerimmunotherapyoncologydrug-combination